Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Unmet Need | Relapsed or Refractory DLBCL | US/EU | 2019

MARKET OUTLOOK

Relapsed/refractory diffuse large B-cell lymphoma (R/RDLBCL) represents an area of high unmet need in non-Hodgkin’s lymphoma (NHL) due to the poor outcomes with current salvage treatment. Rituximab-based chemoimmunotherapy regimens (e.g., R-DHAP, R-ICE, R-ESHAP) are the conventional standard of care for R/RDLBCL followed by conditioning and autologous or allogeneic stem cell transplantation (SCT) in eligible patients. The anti-CD19 CAR T-cell therapies Yescarta (Gilead/Kite) and Kymriah (Novartis) have expanded treatment options for patients with DLBCL, although their current use is restricted to third and subsequent lines of therapy. Despite the evolving market landscape, significant unmet need remains in the treatment of R/RDLBCL due to the limited availability of effective treatment options.

QUESTIONS ANSWERED

What are the most important factors that drive hematologist-oncologists’ prescribing decisions for R/R DLBCL?
How do current therapies perform on key clinical attributes for R/R DLBCL?
What are the major unmet needs and the most lucrative opportunities in R/R DLBCL?
When considering new treatment options in this setting, what trade-offs are acceptable to surveyed hematologist-oncologists between key clinical attributes and cost of therapy?

Markets covered: United States, France, Germany, United Kingdom.

Primary research: Survey of 60 U.S. hematologist-oncologists and 30 European hematologist-oncologists.

Key companies: Gilead, Kite Pharma, Novartis, Roche / Genentech.

Key drugs: Rituximab, Yescarta, Kymriah.

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Contact sales account_box

Report

Gout – Current Treatment – Treatment Algorithms: Claims Data Analysis – Gout (US)

Gout, a form of inflammatory arthritis, arises due to the persistent elevation of serum uric acid (sUA) levels. The condition manifests through sudden and intense gout flares, causing significant…

north_east

Report

Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)

Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…

north_east

Report

Alopecia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alopecia Areata (US)

Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by the targeting of anagen hair follicles by the host immune system, resulting in varying degrees of hair loss. Topical…

north_east

Report

Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)

HCM is a genetic heart condition characterized by thickened myocardium and left ventricular hypertrophy, often linked to sarcomere mutations. While some patients remain asymptomatic, common…

north_east

Report

Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)

The NHL therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced…

north_east

Product logins

Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Unmet Need | Relapsed or Refractory DLBCL | US/EU | 2019

Related Market Assessment Reports

Gout – Current Treatment – Treatment Algorithms: Claims Data Analysis – Gout (US)

Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)

Alopecia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alopecia Areata (US)

Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)

Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)

Follow us

Contact us